DALLAS / Oct 23, 2024 / Business Wire / Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at 12:30 p.m. Eastern time.
A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors. The replay will be available for 30 days.
About Tenet Healthcare
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.
| Last Trade: | US$128.32 |
| Daily Change: | -1.39 -1.07 |
| Daily Volume: | 48,161 |
| Market Cap: | US$12.200B |
October 29, 2024 July 24, 2024 April 30, 2024 February 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
